58
Participants
Start Date
June 1, 2023
Primary Completion Date
July 1, 2026
Study Completion Date
June 1, 2027
Zimberelimab
Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
Domvanalimab
Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
University of Texas Southwestern Medical Center, Dallas
Collaborators (1)
Arcus Biosciences, Inc.
INDUSTRY
Cancer Prevention Research Institute of Texas
OTHER
University of Texas Southwestern Medical Center
OTHER